Ascendis Pharma (ASND)
(Delayed Data from NSDQ)
$136.53 USD
+3.03 (2.27%)
Updated Aug 1, 2024 04:00 PM ET
After-Market: $136.37 -0.16 (-0.12%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Cash flow Statements
Fiscal Year End for Ascendis Pharma AS falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -521.07 | -614.45 | -453.81 | -478.57 | -244.18 |
Depreciation/Amortization & Depletion | 20.47 | 18.92 | 18.21 | 10.79 | 7.49 |
Net Change from Assets/Liabilities | -108.00 | -13.14 | -56.46 | -1.10 | 4.56 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 102.78 | 86.40 | -2.06 | 158.69 | 35.08 |
Net Cash From Operating Activities | -505.82 | -522.27 | -494.12 | -310.19 | -197.05 |
Property & Equipment | -2.59 | -5.22 | -28.67 | -18.85 | -5.78 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 312.64 | 70.26 | -102.15 | -313.79 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 310.05 | 65.04 | -130.83 | -332.64 | -5.78 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 11.13 | -105.52 | 423.33 | 729.70 | 592.85 |
Issuance (Repayment) of Debt | 147.47 | 530.26 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | -11.30 | -6.70 | -7.61 | -5.45 | -4.52 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -1.96 | 0.00 | 0.00 | -35.84 | -35.51 |
Net Cash from Financing Activities | 145.34 | 418.04 | 415.73 | 688.41 | 552.82 |
Effect of Exchange Rate Changes | -6.50 | 37.61 | 45.66 | -61.10 | 8.68 |
Net Change In Cash & Equivalents | -56.93 | -1.58 | -163.56 | -15.52 | 358.67 |
Cash at Beginning of Period | 481.37 | 470.19 | 691.54 | 683.22 | 311.21 |
Cash at End of Period | 424.44 | 468.61 | 527.98 | 667.69 | 669.88 |
Diluted Net EPS | -9.25 | -10.96 | -8.28 | -9.46 | -5.25 |
Fiscal Year End for Ascendis Pharma AS falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -142.26 | -521.07 | -429.45 | -253.35 |
Depreciation/Amortization & Depletion | NA | 4.86 | 20.47 | 15.17 | 10.02 |
Net Change from Assets/Liabilities | NA | -56.28 | -108.00 | -77.80 | -62.06 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 83.40 | 102.78 | 29.63 | -21.92 |
Net Cash From Operating Activities | NA | -110.29 | -505.82 | -462.45 | -327.31 |
Property & Equipment | NA | -0.22 | -2.59 | -2.68 | -1.67 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 7.98 | 312.64 | 307.24 | 282.56 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 7.77 | 310.05 | 304.56 | 280.89 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 23.03 | 11.13 | 9.00 | 2.26 |
Issuance (Repayment) of Debt | NA | -3.02 | 147.47 | 152.14 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | -11.30 | -8.38 | -5.54 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | -1.96 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 20.00 | 145.34 | 152.75 | -3.28 |
Effect of Exchange Rate Changes | NA | 4.43 | -6.50 | 1.33 | -5.41 |
Net Change In Cash & Equivalents | NA | -78.09 | -56.93 | -3.81 | -55.11 |
Cash at Beginning of Period | NA | 425.77 | 481.37 | 484.08 | 484.97 |
Cash at End of Period | NA | 347.68 | 424.44 | 480.28 | 429.86 |
Diluted Net EPS | NA | -2.50 | -1.64 | -3.14 | -2.36 |